APC: USP accepting comments on pending monographs

Tattoos, legal counsel, and good info

If APC had a tattoo on its bicep — if we had a bicep, I mean — it might well read “Consult legal counsel.” read more →
State advocacy update

APC sent a letter to the New Mexico Board of Pharmacy this week commenting on its proposed amendments that would align the state with USP (good), but would also require that pharmacists ensure all flavors are inert (yikes). read more →
Board approves new officer succession

The APC Board of Directors has voted to name Gina Besteman (previously vice president) the board chair-elect after the resignation of Michelle Moser from the position. Besteman will assume the chair in January 2025. read more →
FDA is concerned about compounded GLP-1 dosing errors

Earlier this week APC received a letter from the FDA explaining the agency's concerns regarding dosing and patient usage of compounded semaglutide and tirzepatide. read more →
Did you get your Compounding Pharmacy Snapshot?

If you haven’t already, don’t forget to download and share the 2023-2024 edition of our Snapshot of Pharmacy Compounding in America. read more →
After report, FTC to sue PBMs

On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs. read more →

March 5, 2021

USP accepting comments on pending monographs

Did you know that USP allows input for its Pending Monograph Program? Now you do. The organization doesn’t make a formal announcement the way, say, FDA would, but it does publish ‘notices of intent’ for revisions, and “All stakeholders are encouraged to comment on new monograph proposals and revision proposals.”

Click here for the current list of compendial notices for the monograph program.

And click here for an explanation of the process.